Welcome to our dedicated page for Cytodyn SEC filings (Ticker: CYDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CytoDyn Inc. (CYDY) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-assisted context. As a Delaware-incorporated, clinical-stage biotechnology and oncology company trading on the OTCQB, CytoDyn files a variety of documents that detail its clinical strategy, governance, capital structure, and material events.
Key filings for CYDY include current reports on Form 8‑K, which the company uses to report significant developments. Recent 8‑Ks describe an agreement in principle to settle a securities class action lawsuit, including the contemplated mix of cash and common stock, and a Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) that outlines terms under which CytoDyn may sell common stock over a multi‑year period. Another 8‑K and related proxy materials document stockholder approval of an amendment to increase the total number of authorized shares of common stock and the filing of a corresponding Certificate of Amendment in Delaware.
CytoDyn’s definitive proxy statement on Schedule DEF 14A provides additional insight into corporate governance, annual meeting agendas, advisory votes on executive compensation, auditor selection, and proposals related to share authorization. The proxy statement also explains how the company solicits votes, conducts virtual stockholder meetings, and structures its board elections.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the main points of each document, helping readers quickly understand complex legal and financial language. Real-time updates from EDGAR ensure that new 8‑Ks, proxy statements, and other reports appear promptly, while structured data makes it easier to track items such as amendments to the certificate of incorporation, equity financing arrangements, and outcomes of stockholder votes.
For investors analyzing CYDY, the SEC filings page is a primary source for understanding how CytoDyn manages its capital, responds to litigation, and formalizes decisions that affect shareholders, all grounded in the company’s official regulatory disclosures.
CytoDyn Inc. is registering 278,076,375 shares of common stock for resale by existing selling stockholders, including 184,135,636 outstanding shares and 93,940,739 shares issuable upon exercise of warrants. CytoDyn will not receive proceeds from these resales but may receive up to approximately $23.9 million if the covered warrants are exercised for cash.
The company is a clinical-stage biotech focused on developing its CCR5-targeting antibody leronlimab, particularly in solid-tumor oncology such as microsatellite stable colorectal cancer and metastatic triple‑negative breast cancer. CytoDyn’s financial position is strained: as of April 15, 2026 it held about $13.4 million in unrestricted cash against roughly $29.3 million of accounts payable and accrued liabilities as of February 28, 2026, and its auditors issued a going concern opinion for the year ended May 31, 2025.
The filing highlights reliance on additional financing, dilution risk from extensive prior and potential future equity issuances, legal exposures including a proposed settlement of a federal securities class action for $500,000 in cash and 49 million shares, and typical biotech risks around clinical trials, regulatory approvals, dependence on third parties, and protection of intellectual property.
CytoDyn Inc. updates its prospectus supplement to register up to 375,999,668 shares of common stock, reflecting resale of 181,324,099 shares and 194,675,569 shares underlying warrants. This supplement incorporates CytoDyn’s Form 10-Q for the quarter ended February 28, 2026.
The company reported $15.7M in cash and cash equivalents and an accumulated deficit of $920.6M as of February 28, 2026, and the consolidated financials disclose substantial doubt about the company’s ability to continue as a going concern. The 10-Q records a legal settlement accrual revalued to $12.7M and an agreement in principle providing for $500,000 cash plus 49 million shares as a prospective class-action settlement, subject to documentation and court approval.
CytoDyn Inc. updates a prospectus supplement registering up to 375,999,668 shares of common stock for resale by selling stockholders. The supplement states this total comprises 181,324,099 shares offered directly and 194,675,569 shares underlying warrants.
The supplement incorporates a Form 8-K dated March 24, 2026, disclosing that the company extended two secured convertible promissory notes originally issued in 2021 by 36 months. As consideration, CytoDyn agreed to make monthly payments totalling $1,000,000 in shares (priced at the lower of the prior trading day close or a five-day average) through the new maturities in April 2029, and reduced the annual interest rate on each note to 5%.
CytoDyn Inc. director Tanya Durkee Urbach received a grant of non-qualified stock options covering 574,385 shares of common stock at an exercise price of $0.2800 per share. The grant was approved by the Compensation Committee on March 20, 2026, as her annual fiscal 2026 award under CytoDyn's 2012 Equity Incentive Plan.
The options vest in 12 approximately equal monthly installments from April 2026 through March 2027, contingent on continued service. Following this grant, Urbach holds stock options for 574,385 underlying shares directly.
CytoDyn Inc. director Stephen M. Simes received a grant of 574,385 non-qualified stock options to buy common stock at $0.28 per share. The award was approved on March 20, 2026 as his regular annual grant under CytoDyn’s 2012 Equity Incentive Plan.
The options expire on March 20, 2036 and vest in 12 approximately equal monthly installments from April 2026 through March 2027, contingent on his continued service. Following this grant, Simes holds 574,385 derivative securities representing the right to acquire the same number of common shares.
CytoDyn Inc. director Lishomwa C. Ndhlovu received a non-qualified stock option grant covering 574,385 shares of common stock at an exercise price of $0.28 per share. The option expires on March 20, 2036 and was approved as the annual grant for fiscal year 2026 under CytoDyn's 2012 Equity Incentive Plan.
The award vests in 12 approximately equal monthly installments for continuous service from April 2026 through March 2027. After this grant, Ndhlovu holds stock options for 574,385 shares directly.
CytoDyn Inc. reported that Chief Executive Officer Jacob P. Lalezari received a grant of non-qualified stock options for 4,874,691.0000 shares of common stock at an exercise price of $0.2800 per share as his annual fiscal 2026 award under the 2012 Equity Incentive Plan.
According to the vesting schedule, 1,218,672 underlying shares will vest on March 20, 2027, with the remaining options vesting in approximately equal monthly installments from April 2027 through March 2030, subject to continuous service. This is a compensation-related, non-market transaction.
CytoDyn Inc. reported that Chief Financial Officer Robert E. Hoffman received a grant of non-qualified stock options covering 4,874,691 shares of common stock. The options have an exercise price of $0.28 per share and expire on March 20, 2036.
This award represents his annual equity grant for fiscal year 2026 under CytoDyn's 2012 Equity Incentive Plan. Vesting is time-based: 1,218,672 shares vest on March 20, 2027, with the remaining options vesting in approximately equal monthly installments from April 2027 through March 2030, contingent on continued service.
CytoDyn Inc. director Dunlap Ryan reported receiving a grant of non-qualified stock options to buy 574,385 shares of common stock. The options have an exercise price of $0.28 per share and expire in March 2036. This award represents his annual fiscal 2026 grant under CytoDyn's 2012 Equity Incentive Plan.
The options vest in 12 approximately equal monthly installments from April 2026 through March 2027, conditioned on continued service. After this grant, Ryan holds 574,385 derivative securities, and the filing does not show any open-market purchases or sales of CytoDyn common stock.